Skip to main content
. 2025 Aug 8;16:1591136. doi: 10.3389/fphar.2025.1591136

TABLE 2.

Occurrence of adverse reactions.

Adverse reactions Incidence rate (n, %)
Experimental Control
Dry mouth 5 (0.89) 5 (0.90)
Nausea 11 (1.95) 8 (1.44)
Diarrhea 7 (1.24) 7 (1.26)
Dizziness 2 (0.36) 1 (0.18)
Skin itching 3 (0.53) 0
Increased heart rate 1 (0.18) 1 (0.18)
Edema 2 (0.36) 4 (0.72)
Rash 3 (0.53) 8 (1.44)
Palpitations 2 (0.36) 0
Chest tightness 1 (0.18) 0
Constipation 1 (0.18) 2 (0.36)
Indigestion 1 (0.18) 1 (0.18)
Headache 3 (0.53) 5 (0.90)
Thrombophlebitis 1 (0.18) 2 (0.36)
Liver and kidney injury 1 (0.18) 1 (0.18)
Muscle spasm 1 (0.18) 1 (0.18)
Gastrointestinal reactions 3 (0.53) 1 (0.18)
Dyspnea 1 (0.18) 2 (0.36)
Gastric distension and nausea 0 1 (0.18)
Vomiting 0 1 (0.18)
Elevated alanine aminotransferase 1 (0.18) 0